Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China

Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China

ABSTRACT Background Enfortumab vedotin, a fully human monoclonal antibody–drug conjugate (ADC) directed to Nectin‐4, prolonged overall survival (OS) versus standard chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma (mUC) previously receiving a progr...

Full description

Saved in:
Bibliographic Details
Main Authors: Siming Li, Yanxia Shi, Haiying Dong, Hongqian Guo, Yu Xie, Zhongquan Sun, Xiaoping Zhang, Eric Kim, Jun Zhang, Yue Li, Chenming Xu, Haishan Kadeerbai, Sue Lee, Seema Gorla, Jun Guo, Xinan Sheng
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Cancer Medicine
Subjects:
antibody–drug conjugates
efficacy
monomethyl auristatin E
safety
urothelial carcinoma
Online Access:https://doi.org/10.1002/cam4.70368
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70368

Similar Items